

Dorothee Oberdhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7676661/publications.pdf>

Version: 2024-02-01

23
papers

349
citations

1040056

9
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

415
citing authors

#	ARTICLE	IF	CITATIONS
1	Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. <i>Kidney International</i> , 2013, 84, 1278-1286.	5.2	72
2	Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. <i>American Journal of Kidney Diseases</i> , 2015, 65, 833-841.	1.9	68
3	Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions. <i>Pharmacoeconomics</i> , 2019, 37, 597-608.	3.3	46
4	Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. <i>American Journal of Kidney Diseases</i> , 2018, 71, 225-235.	1.9	36
5	The societal economic burden of autosomal dominant polycystic kidney disease in the United States. <i>BMC Health Services Research</i> , 2020, 20, 126.	2.2	26
6	Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 123.	1.9	21
7	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology's Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263.	1.9	21
8	The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. <i>Kidney International Reports</i> , 2020, 5, 801-812.	0.8	16
9	<p>Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1619-1643.	2.2	10
10	Polycystic Kidney Disease's Related Disease Burden in Adolescents With Autosomal Dominant Polycystic Kidney Disease: An International Qualitative Study. <i>Kidney Medicine</i> , 2022, 4, 1004-15.	2.0	7
11	Health-Related Quality Of Life (Hrql) Measures In Autosomal Dominant Polycystic Kidney Disease (Adpkd). <i>Value in Health</i> , 2015, 18, A512.	0.3	6
12	A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. <i>Kidney International Reports</i> , 2020, 5, 790-800.	0.8	6
13	Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD. <i>Kidney International Reports</i> , 2022, 7, 1037-1048.	0.8	6
14	Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021, Volume 14, 105-115.	1.8	4
15	Psychometric analyses of patient-reported outcome instruments for autosomal dominant polycystic kidney disease. <i>Value in Health</i> , 2013, 16, A183.	0.3	1
16	[P4's557]: FAMILY AND CAREGIVER SPILLOVER EFFECTS IN ALZHEIMER'S DISEASE COST-EFFECTIVENESS ANALYSES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1565.	0.8	1
17	Impact of Autosomal Dominant Polycystic Kidney Disease (ADPKD) on Caregivers and Families. <i>Value in Health</i> , 2018, 21, S109-S110.	0.3	1
18	Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage. <i>Journal of Medical Economics</i> , 2021, 24, 193-201.	2.1	1

#	ARTICLE	IF	CITATIONS
19	PUK18 THE IMPACT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) ON PATIENTS' HEALTH RELATED QUALITY OF LIFE (HRQOL): DEVELOPMENT OF A CONCEPTUAL FRAMEWORK. Value in Health, 2011, 14, A77.	0.3	0
20	Economic burden and resource use associated with autosomal dominant polycystic kidney disease among a medicare population. Value in Health, 2013, 16, A181.	0.3	0
21	Health-Related Quality of Life (HRQOL) in Adolescents with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Value in Health, 2018, 21, S114-S115.	0.3	0
22	PUK10 SOCIETAL BURDEN OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) IN THE UNITED STATES: BEYOND HEALTHCARE COSTS. Value in Health, 2019, 22, S382.	0.3	0
23	Developing a Conceptual Disease Model of Patient Experiences and Identifying Patient-Reported Clinical Outcome Assessments for Use in Trials of Treatments for Focal Onset Seizures. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 611-631.	2.2	0